A randomized trial and the treatment of Pemphigus vulgaris

Abstract

Pemphigus vulgaris is a rare, life-threatening autoimmune disease. Mycophenolate mofetil is a potent immunosuppressant medication approved by the Food and Drug Administration to be used after solid organ transplantation and to treat pemphigus vulgaris. Mycophenolate mofetil has not become the wonder drug that had been anticipated based on initial clinical reports. Studies like that reported by Beissert et al. in this issue are essential to improve dermatologic care. © 2010 The Society for Investigative Dermatology.